Monte Rosa Therapeutics
GLUE | NASDAQ
$9.16
-$0.21 (-2.24%)
At close: Nov 16, 2026, 4:00 PM ET
$9.16
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 5:56 PM ET
Monte Rosa Therapeutics Company Profile
Company profile explainedCompany Profile
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Markus Warmuth | President, Chief Executive Officer & Director |
| Jennifer Champoux | Chief Operating Officer |
| Magnus Walter DPHIL | Chief Technology Officer |
| Andrew Funderburk | Chief Investor Relations and Strategy Officer |
| Filip Janku | Chief Medical Officer |
| John C. Castle | Chief Data & Information Officer |
| Matthew Bowen | Corporate Controller & Principal Accounting Officer |
| Phil Nickson | Chief Business & Legal Officer |
| Sharon Townson | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 06, 2026 | 4 | Filing |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 17, 2026 | 4 | Filing |
| Jul 16, 2026 | 4 | Filing |
| Jul 08, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Monte Rosa Therapeutics
| Country | United States |
| IPO Date | Jun 24, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 173 |
| CEO | Markus Warmuth |
Contact Details
321 Harrison Avenue Boston,
Massachusetts 02118 United States
Stock Details
| Ticker Symbol | GLUE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001826457 |
| CUSIP Number | 61225M102 |
| ISIN Number | US61225M1027 |
| SIC Code | 2836 |
Recent News
- 2 months ago / seekingalpha.comMonte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
- 2 months ago / benzinga.comMonte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease
- 2 months ago / seekingalpha.comMonte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet
- 3 months ago / globenewswire.comMonte Rosa Therapeutics to Participate in Upcoming Investor Conferences
- 3 months ago / zacks.comMonte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
- 5 months ago / fool.comAfter a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
- 5 months ago / seekingalpha.comMonte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential
- 6 months ago / zacks.comMonte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
- 7 months ago / fool.comMonte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
- 8 months ago / zacks.comMonte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Add to Watchlist
Select watchlists to add or remove GLUE